

May 21, 2024

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited had vide its letter dated August 16, 2018 informed the receipt of marketing authorization for Olaparib (Lynparza) 100mg and 150 mg tablets which was also indicated for the treatment of patient with gBRCA mutation and advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

Through this letter we wish to inform that the Company has now received permission for voluntary withdrawal of the above-mentioned indication of Olaparib (Lynparza) 100mg and 150 mg tablets from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.

We request you to take the above intimation on record.

Thanking you
Yours faithfully

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary